Market Overview

5 Biotechs With Catalysts Coming This Week

Share:
5 Biotechs With Catalysts Coming This Week
Related OPHT
Do Analysts See A Path Forward For Ophthotech's Fovista?
20 Biggest Mid-Day Losers For Tuesday
Related REGN
25 Stocks Moving In Thursday's Pre-Market Session
Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected

In a report issued Monday, Chardan Capital Markets’ Managing Director and Head of Healthcare Research Gbola Amusa looked into five biotech and pharmaceutical companies with catalysts coming this week.

Regeneron: Buy, $565.00 PT

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is scheduled to announce its second-quarter financial results before the market opens on Tuesday. Chardan believes the company “should perform on the Praluent ramp in cholesterol management, en route to Praluent achieving mega-blockbuster status ($8.0 billion in 2021 sales).”

For the second quarter of 2015 and the full year, the firm expects earnings and sales figures above consensus. However, the analysts do not expect the company to trade on 2015 and “are more interested in any management feedback that affects 2016 and beyond financials, especially since 2015 will have stocking, ramp costs, and other items that would make financials atypical.”

Related Link: Even With Recent Declines, Investors Still Love Biotech ETFs

Ophthotech: Top Pick, Buy, $105.00 PT

Small-cap Ophthotech Corp (NASDAQ: OPHT) will report its second-quarter results on Wednesday morning. However, Amusa does not expect a lot of news in the call, but does see it as an opportunity for shareholders to learn more about the Fovista-Novartis story.

Novartis AG (ADR) (NYSE: NVS) has agreed to pay millions in royalties and milestones for Fovista sales, and the analyst believes “Novartis could potentially in part finance an OPHT acquisition from likely milestone payments, by acting sooner, or otherwise may have to pay potentially $5 billion-$10 billion (or more) in 2016 or later, once phase III visibility on OPHT's Fovista emerges.”

The recent purchase of Receptos Inc (NASDAQ: RCPT) by Celgene Corporation (NASDAQ: CELG) supports the acquisition thesis presented above.

VistaGen: Buy, $50.00 PT

Vistagen Therapeutics Inc (OTC: VSTA) is seeing increased investor interest following the acquisition of Naurex by Allergan PLC (NYSE: AGN). The experts comment, “To the extent that Allergan management on its calls talks about Naurex and the mechanism of the new class of anti-depression medicines (NMDAR modulators), that includes VSTA's AV-101, we believe this will support performance for VSTA, which has potentially the first oral anti-depression drug with the mechanism.”

Allergan’s earnings call is scheduled for Thursday morning.

Related Link: How Biotech Stock Trevena Could Almost Triple In Value By 2022

Esperion: Sell, $45.00 PT

Esperion Therapeutics Inc (NASDAQ: ESPR) will report its quarterly financial results on Thursday after the market closes. While Chardan’s questions regarding the company’s cholesterol drug ETC-1002 remain unanswered, they stated that they will try their best to get some answers from the call.

Axovant Sciences: Sell, $9.50 PT

Finally, there’s Axovant Sciences Ltd (NYSE: AXON), a small-cap, clinical-stage biopharmaceutical company. The analysts said it would be good to follow vTv Therapeutics Inc (NASDAQ: VTVT)’s trades from here, as they see a few parallels with Axovant.

Their view is quite simple: They believe Axovant’s shares are “mis-priced/over-valued based on consensus modeling.”

Image Credit: Public Domain

Latest Ratings for OPHT

DateFirmActionFromTo
Dec 2016Gabelli & Co.DowngradesBuyHold
Dec 2016Goldman SachsUpgradesSellNeutral
Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for OPHT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Short Ideas Health Care Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (AGN + ACT)

View Comments and Join the Discussion!